Centre Hospitalier De Lens

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia1 trial
• Atrial fibrillation1 trial
• Cervical cancer1 trial
• Heart failure1 trial
• Liver and biliary tract cancer1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial
• Stroke1 trial

Phase

• Phase 34 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting2 trials
• Completed2 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca1 trial
• Bayer AG1 trial
• Centre Oscar Lambret1 trial
• Fondation Franc.Cancerologie Digestive1 trial
• Poitiers University Hospital1 trial
• and 1 more

Running trials

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

  NCT04751877· Phase 3· Poitiers University Hospital· Source

• Active, not recruiting

  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

  NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting

Closed trials

• Completed

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· Phase 2/3· Fondation Franc.Cancerologie Digestive· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Terminated

  Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer

  NCT04016142· Phase 2· Centre Oscar Lambret· Source